S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Memphasys Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume246,322 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive MEM News and Ratings via Email

Sign-up to receive the latest news and ratings for Memphasys and its competitors with MarketBeat's FREE daily newsletter.

About Memphasys

Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
Book Value
A$0.01 per share





Next Earnings Date
Not Optionable


Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Memphasys (ASX:MEM) Frequently Asked Questions

What stocks does MarketBeat like better than Memphasys?

Wall Street analysts have given Memphasys a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Memphasys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Memphasys' key executives?

Memphasys' management team includes the following people:
  • Ms. Alison Mary Coutts B.E., M.B.A., B.E. (Chem), GDipBiotech, MBA, Exec. Chairman & Interim CEO
  • Pablo Neyertz, Director of Fin.
  • Nick Gorring, Operations Mang.
  • Mr. Malcolm Coleman, Chief Financial Officer of Nusep Ltd
  • Mr. Andrew Metcalfe, Company Sec.

What is Memphasys' stock symbol?

Memphasys trades on the ASX under the ticker symbol "MEM."

How much money does Memphasys make?

Memphasys has a market capitalization of $0.00.

What is Memphasys' official website?

The official website for Memphasys is www.memphasys.com.

How can I contact Memphasys?

The company can be reached via phone at 61 2 8415 7300.

This page was last updated on 10/24/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.